Efficacy and Safety of Twice-Daily Tramadol Hydrochloride Bilayer Sustained-Release Tablets with an Immediate Release Component for Postherpetic Neuralgia: Results of a Phase III, Randomized, Double-Blind, Placebo-Controlled, Treatment-Withdrawal Study.
We investigated the efficacy and safety of twice-daily bilayer sustained-release tramadol hydrochloride tablets (35% immediate-release; 65% sustained-release) in patients with postherpetic neuralgia.
